Orion Corp.

Orion Group Interim report January–March 2026

Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours

Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA

Orion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 2026

Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines